IL20 and cellulitis: One serious AE (SAE) was reported in the trial, during the MD dose-escalation phase (moderate cellulitis reported 19 days after the fourth and final dose of 0.05 mg/kg anti‒IL-20), but this SAE was judged as having no causal relationship to the study drug.